Quest Diagnostics sales and marketing update

Quest launched its Quest Diagnostics Thyroid Cancer Mutation Panel in the U.S. to detect cancer in thyroid biopsies that were indeterminate for cancer based on cytology test methods. The panel identifies mutations in BRAF V600E, Ras, Ret proto-oncogene (RET)/PTC fusion oncoprotein, and paired box gene 8 (PAX8)/ peroxisome proliferation activated receptor (PPAR) gamma fusion protein, which are associated with two common forms of the disease: papillary and follicular thyroid cancer. ...